Sells blood-based lung diagnostic tests to healthcare providers and provides diagnostic testing and development services to biopharmaceutical, life sciences, and diagnostic companies.
10-K for FY2025, filed Feb 26, 2026We derive our revenue from two sources: (i) Biodesix Lung Diagnostic Testing (Lung Diagnostic Testing), providing lung diagnostic testing…View ↗
Our tests support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. We believe our…View ↗
We enable the world’s leading biopharmaceutical, life sciences, and academic research institutions with scientific, technological, and…View ↗
We offer end-to-end diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and…View ↗
Healthcare payers, medical facilities, insurers, or patients are billed for lung tests when results are delivered. Development clients pay for testing and scientific services when results or milestones are delivered, or over the contract term.
10-K for FY2025, filed Feb 26, 2026
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$88.5M
10-K for FY2025, filed Feb 26, 2026
$88.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Diagnostic Tests
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
89%
FY2022: 90%
|
Diagnostic Tests, FY2025
$79.2M Sources
|
Sold outright |
|
Development Services
Mix
10-K for FY2025, filed Feb 26, 2026 |
11% |
Development Services, FY2025
$9.3M Sources
|
Mix |
Healthcare providers order blood-based lung tests for patients; fees are billed to third-party payers, medical facilities, commercial insurers, or patients. Biopharmaceutical, life sciences, diagnostic, and academic research organizations use its development and testing services.
10-K for FY2025, filed Feb 26, 2026Diagnostic Tests revenues consist of blood-based lung tests which are recognized in the amount expected to be received in exchange for…View ↗
For our Biodesix Lung Diagnostic Tests, commercial efforts are focused on the promotion of our tests to healthcare professionals actively…View ↗
We enable the world’s leading biopharmaceutical, life sciences, and academic research institutions with scientific, technological, and…View ↗
We offer end-to-end diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and…View ↗
No. It lost $35.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$8MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Aug 5, 2026
For full year 2026, the Company expects total revenue of $108–114 million, with the midpoint representing approximately 25% growth over…View ↗
Growing. Revenue grew 62% in 4 years, from $54.5M in FY2021 to $88.5M in FY2025, about 13% a year.
Pandemic testing
The earlier report includes pandemic testing among its diagnostic services; the latest describes diagnostic testing as blood-based lung tests and identifies development services as the other revenue source.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Feb 26, 2026
Loading...